Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant TAC with or without zoledronic acid in HER2-negative breast cancer
NL-OMON34755Phase 3Active, not recruiting
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid in breast cancer (2 arms), sponsored by Borstkanker Onderzoek Groep. Primary endpoint: Pathologic complete response. Started Jul 2010; status: active, not recruiting.
02
Drugs
zoledronic acid
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON34755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34755.